ABSTRACT
This chapter discusses anileridine, a neuropsychotropic drug. It presents the approved indications of the drug for neuropsychological disorders, usual dosage and administration, available dosage forms, storage, and compatibility, and the mechanism of action. Information on relative contraindications, clinically significant drug interactions, adverse drug reactions, and overdosage is also provided. Sold under the trade name Leritine®, anileridine is prescribed for the symptomatic management of pain disorders. The drug is given 25 to 50 mg orally every six hours, as needed or 25 to 75 mg intramuscularly or subcutaneously every four to six hours, as needed. Although the exact mechanism of action is not yet fully understood, anileridine appears to elicit its analgesic action primarily by binding to the endorphin receptors in the CNS. Concurrent alcohol use may increase the CNS depressant action of anileridine.
